{"id":"W2116922255","doi":"10.1016/s0140-6736(12)61857-1","title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1401,"is_retracted":false,"has_abstract":false,"ca_institutions":"Mount Sinai Hospital","funders":"National Cancer Institute","keywords":"Regorafenib; Medicine; GiST; Sunitinib; Internal medicine; Placebo; Clinical endpoint; Imatinib; Hazard ratio; Oncology; Clinical trial; Surgery; Colorectal cancer; Cancer; Confidence interval; Stromal cell; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}